[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Shields CL, Shields JA, Armstrong T: Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy. Am J Ophthalmol; 2001 Oct;132(4):576-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy.
  • PURPOSE: To illustrate a novel method of management for extensive conjunctival and corneal melanoma.
  • A 40-year-old Caucasian woman presented with a large, diffuse conjunctival melanoma involving 6 clock hours of the limbus.
  • The remaining bulbar conjunctiva and the entire corneal epithelium were affected by diffuse, flat melanosis.
  • RESULTS: The conjunctival melanoma was completely resected microsurgically in one piece without disrupting the tumor.
  • The corneal melanosis was subsequently treated with topical mitomycin C eyedrops.
  • At 8 months follow-up, the conjunctiva and the cornea were completely healed with resolution of all pigment and 20/20 visual acuity.
  • CONCLUSION: Preliminary evidence suggests that combined therapeutic approaches, consisting of extensive tumor removal, cryotherapy, amniotic membrane allograft, and topical mitomyin C, can be effective in the management of diffuse conjunctival and corneal melanoma arising from primary acquired melanosis.
  • [MeSH-major] Amnion / transplantation. Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Melanoma / therapy. Melanosis / therapy. Mitomycin / therapeutic use. Ophthalmologic Surgical Procedures
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11589886.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


2. Kemp EG, Harnett AN, Chatterjee S: Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol; 2002 Jan;86(1):31-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias.
  • AIMS: To demonstrate the efficacy of mitomycin C as adjuvant therapy preoperatively and intraoperatively in the management of recurrent or diffuse ocular surface neoplasias.
  • METHODS: The case notes of 11 patients receiving mitomycin C adjuvant therapy as 0.04% eye drops four times a day in two weekly courses preoperatively and/or a single intraoperative application of 0.4 mg/ml of mitomycin C were reviewed.
  • RESULTS: All cases showed a favourable response to mitomycin C adjuvant therapy with regression in size or retardation of a rapid growth pattern and no serious sequelae.
  • CONCLUSION: In this series, mitomycin C adjuvant therapy of recurrent or diffuse ocular surface neoplasias was well tolerated and showed favourable clinical results.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma / drug therapy. Eye Neoplasms / drug therapy. Melanoma / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / methods. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Ophthalmic Solutions / administration & dosage. Preoperative Care / methods

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 1999 Nov;128(5):638-40 [10577537.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Am J Ophthalmol. 1979 Jan;87(1):84-6 [434057.001]
  • [Cites] Trans Am Ophthalmol Soc. 1980;78:290-300 [7257061.001]
  • [Cites] Am J Ophthalmol. 1983 Mar;95(3):359-63 [6829682.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1990 Oct;31(10):2136-44 [2211010.001]
  • [Cites] Ophthalmology. 1990 Sep;97(9):1204-10 [2122349.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):317-21 [2023752.001]
  • [Cites] Arch Ophthalmol. 1991 Aug;109(8):1141-6 [1907822.001]
  • [Cites] Trans Am Ophthalmol Soc. 1991;89:285-98; discussion 298-301 [1808811.001]
  • [Cites] Ophthalmology. 1992 Dec;99(12):1809-14 [1480395.001]
  • [Cites] Ophthalmology. 1997 May;104(5):844-8 [9160032.001]
  • [Cites] Ophthalmic Surg Lasers. 1997 Aug;28(8):662-9 [9268998.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • (PMID = 11801499.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1770962
  •  go-up   go-down


3. Kurli M, Finger PT: Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol; 2005 Nov;243(11):1108-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.
  • PURPOSE: To report 12-year follow-up experience with topical mitomycin chemotherapy for diffuse and multifocal primary acquired melanosis (PAM) with atypia and conjunctival melanoma.
  • Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma.
  • Primary treatments consisted of mitomycin 0.04% qid for 28 days (two 14-day cycles) and for 7 consecutive days as adjuvant therapy.
  • RESULTS: Sixteen patients were followed for a mean 81 months (range 13-144 months) after treatment.
  • All tumors responded to chemotherapy.
  • Recurrence was noted in eight (three adjuvant and five primary treatment patients).
  • The mean time to recurrence was 36.9 months.
  • The short-term mitomycin-related complications included transient keratoconjunctivitis (n=14), severe keratoconjunctivitis (n=1) and one corneal abrasion with scar formation.
  • The long-term complications included pannus (n=2) and corneal haze (n=1).
  • Three patients died, one of metastatic conjunctival melanoma.
  • CONCLUSIONS: Conjunctival melanoma and PAM responded to mitomycin 0.04% topical chemotherapy; subepithelial nests appeared resistant to treatment.
  • Treatment-related complications were acceptable.
  • In this series, as primary and adjuvant therapy, topical mitomycin yielded an overall recurrence rate of 50%.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Melanoma / drug therapy. Melanosis / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 2003 Jun;135(6):800-6 [12788119.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):252-9 [8199108.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1998 May;14(3):208-15 [9612814.001]
  • [Cites] Ophthalmology. 1989 Feb;96(2):147-66 [2649838.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):317-21 [2023752.001]
  • [Cites] Ophthalmology. 1982 May;89(5):502-15 [7099571.001]
  • [Cites] Br J Ophthalmol. 1990 Oct;74(10):615-9 [2285686.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Cornea. 2002 Oct;21(7):715-7 [12352093.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):72-8; discussion 79 [9917784.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2567-74 [6790156.001]
  • [Cites] Cornea. 2003 Mar;22(2):114-7 [12605043.001]
  • [Cites] Cornea. 2003 Oct;22(7):627-39 [14508259.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1617-22 [10845577.001]
  • [Cites] Trans Am Ophthalmol Soc. 1980;78:467-502 [7257067.001]
  • [Cites] Surv Ophthalmol. 2001 Mar-Apr;45(5):416-44 [11274695.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1012-6 [12750105.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):244-5 [11815356.001]
  • [Cites] Ophthalmology. 1995 Oct;102(10):1569-71 [9097808.001]
  • [Cites] Am J Ophthalmol. 1992 Oct 15;114(4):503-4 [1415465.001]
  • [Cites] Cornea. 2002 Nov;21(8):838-9 [12410049.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Ophthalmology. 1988 Aug;95(8):1058-70 [3231444.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1996 Sep;234(9):569-72 [8880155.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Br J Ophthalmol. 1994 Jul;78(7):520-8 [7522545.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1756-60; discussion 1761 [10485547.001]
  • [Cites] Ophthalmology. 1988 Jun;95(6):813-21 [3211484.001]
  • [Cites] Arch Ophthalmol. 1980 Aug;98(8):1385-9 [7417073.001]
  • [Cites] Br J Ophthalmol. 1993 Oct;77(10):624-30 [8218029.001]
  • (PMID = 15940485.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


Advertisement
4. Abraham LM, Selva D, Casson R, Leibovitch I: Mitomycin: clinical applications in ophthalmic practice. Drugs; 2006;66(3):321-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drug is a bioreductive alkylating agent that undergoes metabolic reductive activation, and has various oxygen tension-dependent cytotoxic effects on cells, including the cross-linking of DNA.
  • It is widely used systemically for the treatment of malignancies, and has gained popularity as topical adjunctive therapy in ocular and adnexal surgery over the past 2 decades.
  • Hence, it has been used as adjunctive therapy in various ocular surgeries, such as glaucoma filtering surgeries, dacryocystorhinostomy, corneal refractive surgery and surgeries for ocular cicatrisation.
  • In addition, it has been used as an adjunct in the surgical management of pterygia, ocular surface squamous neoplasia, primary acquired melanosis with atypia and conjunctival melanoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Cicatrix / prevention & control. Conjunctival Neoplasms / drug therapy. Glaucoma / drug therapy. Melanoma / drug therapy. Mitomycin / therapeutic use. Neoplasms, Squamous Cell / drug therapy. Postoperative Complications / prevention & control
  • [MeSH-minor] Humans. Ophthalmology / trends. Randomized Controlled Trials as Topic. Trabeculectomy. Wound Healing / drug effects

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Glaucoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Scars.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Glaucoma. 1998 Aug;7(4):240-6 [9713781.001]
  • [Cites] Br J Ophthalmol. 1997 Jul;81(7):584-9 [9290375.001]
  • [Cites] Ophthalmology. 2002 May;109(5):985-91 [11986108.001]
  • [Cites] Arch Ophthalmol. 1993 May;111(5):632-5 [8489443.001]
  • [Cites] J Cataract Refract Surg. 2001 Nov;27(11):1854-63 [11709261.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Ophthalmic Surg Lasers. 1997 Dec;28(12):992-7 [9427986.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2000 Mar;16(2):114-8 [10749157.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):248-55 [12040282.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Apr;78(2):216-20 [10794261.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Am J Ophthalmol. 1996 Nov;122(5):728-30 [8909216.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Br J Ophthalmol. 2004 Aug;88(8):995-7 [15258011.001]
  • [Cites] Ophthalmology. 1984 Jun;91(6):673-8 [6462625.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Feb;39(2):449-54 [9478007.001]
  • [Cites] Ophthalmology. 1989 Nov;96(11):1612-4 [2694049.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1998 May;14(3):208-15 [9612814.001]
  • [Cites] J Cataract Refract Surg. 1998 Feb;24(2):249-55 [9530601.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Br J Ophthalmol. 2005 Apr;89(4):449-53 [15774922.001]
  • [Cites] J Glaucoma. 1998 Aug;7(4):230-6 [9713779.001]
  • [Cites] J Glaucoma. 1997 Oct;6(5):293-7 [9327347.001]
  • [Cites] Arch Ophthalmol. 1982 Nov;100(11):1758-62 [7138343.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Feb;241(2):106-10 [12605264.001]
  • [Cites] Clin Eye Vis Care. 2000 Dec;12(3-4):185-188 [11137435.001]
  • [Cites] Mutat Res. 1987 Jul;179(1):75-88 [3110608.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1999 Jan;15(1):19-22 [9949424.001]
  • [Cites] Cornea. 2004 Jan;23 (1):89-92 [14701965.001]
  • [Cites] Clin Exp Ophthalmol. 2003 Jun;31(3):199-205 [12786769.001]
  • [Cites] J Glaucoma. 2001 Jun;10(3):145-51 [11442174.001]
  • [Cites] Cornea. 2003 Apr;22(3):210-3 [12658084.001]
  • [Cites] Cornea. 2005 Mar;24(2):141-50 [15725881.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 1967 Apr;71(4):351-8 [6070608.001]
  • [Cites] Br J Ophthalmol. 1994 Dec;78(12):888-91 [7819168.001]
  • [Cites] Br J Ophthalmol. 1998 Jan;82(1):63-6 [9536884.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Am J Ophthalmol. 2004 Mar;137(3):583-5 [15013895.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):289-92 [10684840.001]
  • [Cites] Am J Ophthalmol. 1995 Aug;120(2):151-60 [7639298.001]
  • [Cites] Surv Ophthalmol. 2003 May-Jun;48(3):314-46 [12745005.001]
  • [Cites] Ophthalmologica. 1993;207(3):162-4 [8278183.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1624-8 [8233386.001]
  • [Cites] Am J Ophthalmol. 1994 Sep 15;118(3):332-7 [8085590.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2001 Mar;17(2):115-9 [11281583.001]
  • [Cites] Ophthalmology. 1998 Oct;105(10):1915-20 [9787364.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):72-8; discussion 79 [9917784.001]
  • [Cites] Ophthalmology. 2004 Jun;111(6):1071-6 [15177955.001]
  • [Cites] Am J Ophthalmol. 1988 Dec 15;106(6):715-8 [3143266.001]
  • [Cites] J Ocul Pharmacol Ther. 2002 Jun;18(3):251-64 [12099546.001]
  • [Cites] Arch Ophthalmol. 1980 Aug;98(8):1390-6 [7417074.001]
  • [Cites] Arch Soc Esp Oftalmol. 2002 Sep;77(9):501-6 [12221542.001]
  • [Cites] Ophthalmology. 1996 Apr;103(4):674-7 [8618770.001]
  • [Cites] Ophthalmology. 1997 Jan;104(1):143-9 [9022119.001]
  • [Cites] Ophthalmology. 1996 Nov;103(11):1934-42 [8942892.001]
  • [Cites] Cornea. 2002 Jan;21(1):12-6 [11805500.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Br J Ophthalmol. 2000 Sep;84(9):1056-7 [10966966.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1425-8 [15489487.001]
  • [Cites] Cornea. 2004 May;23(4):326-9 [15097124.001]
  • [Cites] J Refract Surg. 2001 May-Jun;17(3):342-9 [11383766.001]
  • [Cites] Br J Ophthalmol. 2002 Jan;86(1):31-4 [11801499.001]
  • [Cites] Ophthalmology. 1997 May;104(5):844-8 [9160032.001]
  • [Cites] Arch Ophthalmol. 1998 Apr;116(4):443-7 [9565040.001]
  • [Cites] Ophthalmology. 1997 Oct;104(10):1616-21 [9331200.001]
  • [Cites] Br J Ophthalmol. 1987 Feb;71(2):152-7 [3828266.001]
  • [Cites] Arch Ophthalmol. 1996 Aug;114(8):943-9 [8694729.001]
  • [Cites] Ophthalmology. 1998 Jul;105(7):1222-6 [9663225.001]
  • [Cites] Br J Ophthalmol. 1998 Sep;82(9):1039-41 [9893595.001]
  • [Cites] Ophthalmology. 1997 Jan;104(1):86-91 [9022109.001]
  • [Cites] Clin Exp Ophthalmol. 2004 Oct;32(5):501-4 [15498062.001]
  • [Cites] Curr Opin Ophthalmol. 2000 Aug;11(4):224-32 [10977766.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1012-6 [12750105.001]
  • [Cites] Cornea. 2003 Oct;22(7):598-603 [14508255.001]
  • [Cites] Arch Ophthalmol. 1999 Apr;117(4):457-60 [10206572.001]
  • [Cites] Ophthalmic Surg. 1995 May-Jun;26(3):237-40 [7651691.001]
  • [Cites] Ophthalmology. 1996 Nov;103(11):1946-55 [8942894.001]
  • [Cites] Ophthalmic Surg Lasers. 2002 Mar-Apr;33(2):102-8 [11942540.001]
  • [Cites] Ophthalmic Surg. 1993 Feb;24(2):123-4 [8446348.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1607-11 [12208706.001]
  • [Cites] Br J Ophthalmol. 2001 Jun;85(6):686-8 [11371489.001]
  • [Cites] J Cataract Refract Surg. 2003 Apr;29(4):769-77 [12686247.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):249-52 [11825803.001]
  • [Cites] Ophthalmology. 2002 Jul;109(7):1336-41; discussion 1341-2 [12093659.001]
  • [Cites] Ophthalmology. 1992 Feb;99(2):203-7 [1553208.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):306-10 [12578771.001]
  • [Cites] Curr Opin Ophthalmol. 1998 Aug;9(4):35-9 [10387466.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):89-94 [10647725.001]
  • [Cites] Curr Opin Ophthalmol. 2005 Oct;16(5):303-7 [16175044.001]
  • [Cites] Ophthalmology. 1995 Jul;102(7):1065-70 [9121754.001]
  • [Cites] Ophthalmology. 1997 Jun;104(6):996-1001; discussion 1002-3 [9186441.001]
  • [Cites] Cornea. 1994 May;13(3):219-24 [8033571.001]
  • [Cites] Ophthalmic Res. 2001 Nov-Dec;33(6):340-4 [11721187.001]
  • [Cites] Ophthalmic Surg Lasers. 1996 Jul;27(7):600-4 [9240777.001]
  • [Cites] Arch Ophthalmol. 1991 Aug;109(8):1141-6 [1907822.001]
  • [Cites] Ophthalmic Surg Lasers. 1997 Jul;28(7):539-50 [9243656.001]
  • [Cites] J Ocul Pharmacol. 1990 Fall;6(3):175-82 [2127056.001]
  • [Cites] Ophthalmology. 1998 May;105(5):901-4; discussion 904-5 [9593395.001]
  • [Cites] Ophthalmology. 2000 Feb;107(2):263-9 [10690822.001]
  • [Cites] Arch Ophthalmol. 2003 Jan;121(1):48-56 [12523884.001]
  • [Cites] CLAO J. 1992 Apr;18(2):112-6 [1606673.001]
  • [Cites] Anticancer Drugs. 1990 Oct;1(1):5-13 [2131038.001]
  • [Cites] Ophthalmology. 1997 Apr;104(4):719-24 [9111269.001]
  • [Cites] Ophthalmic Surg. 1994 Sep-Oct;25(9):612-5 [7831005.001]
  • [Cites] J Cataract Refract Surg. 1994 Mar;20 Suppl:216-22 [8006790.001]
  • [Cites] J Glaucoma. 2005 Feb;14(1):52-6 [15650605.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Am J Ophthalmol. 2005 Feb;139(2):229-34 [15733981.001]
  • [Cites] J Glaucoma. 2005 Apr;14(2):172-4 [15741822.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1996 Sep;234(9):569-72 [8880155.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):2024-8 [9098312.001]
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • [Cites] Curr Opin Ophthalmol. 1996 Apr;7(2):24-33 [10163318.001]
  • [Cites] Ophthalmology. 1995 Jan;102(1):70-5 [7831045.001]
  • [Cites] Curr Eye Res. 2001 May;22(5):348-52 [11600935.001]
  • [Cites] Br J Ophthalmol. 1996 Dec;80(12):1087-91 [9059276.001]
  • [Cites] Cornea. 1994 Sep;13(5):411-3 [7995063.001]
  • [Cites] Clin Exp Ophthalmol. 2005 Aug;33(4):433-4 [16033367.001]
  • [Cites] Eye (Lond). 1993;7 ( Pt 5):652-5 [8287987.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Eur J Ophthalmol. 2004 Nov-Dec;14(6):461-3 [15638092.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Eye (Lond). 1993;7 ( Pt 4):584-90 [8253244.001]
  • [Cites] Br J Ophthalmol. 1998 Jan;82(1):29-34 [9536876.001]
  • [Cites] Ophthalmology. 2005 May;112(5):896-903 [15878073.001]
  • [Cites] Ophthalmic Epidemiol. 1999 Sep;6(3):219-28 [10487976.001]
  • [Cites] Br J Ophthalmol. 2004 Jan;88(1):17-8 [14693762.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1756-60; discussion 1761 [10485547.001]
  • [Cites] Ophthalmology. 1985 Nov;92(11):1461-70 [4080320.001]
  • [Cites] Ophthalmology. 1992 Sep;99(9):1471-6 [1407982.001]
  • [Cites] Ophthalmology. 1988 Jun;95(6):813-21 [3211484.001]
  • [Cites] J Cataract Refract Surg. 2005 Feb;31(2):291-6 [15767148.001]
  • [Cites] Cornea. 2005 May;24(4):443-8 [15829803.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(1):CD002897 [11279773.001]
  • [Cites] J Cataract Refract Surg. 2002 Dec;28(12):2088-95 [12498842.001]
  • [Cites] Br J Ophthalmol. 2000 Aug;84(8):903-6 [10906101.001]
  • [Cites] Ophthalmic Surg Lasers. 1999 Jun;30(6):473-80 [10392736.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 2001 May-Jun;38(3):131-5; quiz 172-3 [11386644.001]
  • [Cites] Ophthalmology. 1992 Aug;99(8):1209-19 [1513573.001]
  • [Cites] Eye (Lond). 1997;11 ( Pt 5):649-55 [9474312.001]
  • [Cites] J Glaucoma. 2004 Jun;13(3):228-32 [15118468.001]
  • [Cites] Am J Ophthalmol. 1971 Oct;72(4):679-90 [4938987.001]
  • [Cites] J Glaucoma. 1998 Apr;7(2):86-92 [9559493.001]
  • [Cites] Ophthalmology. 2003 Apr;110(4):734-42 [12689895.001]
  • [Cites] Ophthalmology. 1994 Sep;101(9):1565-74 [7522315.001]
  • [Cites] Arch Ophthalmol. 1971 May;85(5):586-91 [4932288.001]
  • [Cites] Ophthalmology. 2003 Jan;110(1):93-100 [12511352.001]
  • [Cites] Arch Ophthalmol. 2005 Feb;123(2):166-70 [15710811.001]
  • [Cites] J Glaucoma. 1998 Feb;7(1):39-44 [9493114.001]
  • [Cites] Ophthalmology. 2005 Feb;112(2):208-18; discussion 219 [15691552.001]
  • [Cites] Am J Ophthalmol. 1998 Mar;125(3):346-52 [9512152.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Ophthalmology. 1998 Feb;105(2):336-41 [9479296.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1949-52 [9098301.001]
  • [Cites] Ophthalmology. 1994 Apr;101(4):759-62 [8152772.001]
  • [Cites] Surv Ophthalmol. 1988 Jul-Aug;33(1):41-9 [3051468.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Cornea. 2001 Jan;20(1):24-9 [11188998.001]
  • [Cites] Curr Opin Ophthalmol. 2004 Feb;15(1):61-6 [14743022.001]
  • [Cites] Br J Ophthalmol. 2003 Jul;87(7):850-2 [12812883.001]
  • [Cites] Ophthalmic Surg. 1993 Mar;24(3):152-70 [8483566.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2126-35 [9400775.001]
  • [Cites] J Refract Surg. 2004 Mar-Apr;20(2):176-81 [15072318.001]
  • (PMID = 16526821.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Number-of-references] 172
  •  go-up   go-down


5. Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM: Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res; 2004 May 15;64(10):3586-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro, GFA-116 inhibits angiogenesis as measured by inhibition of migration and formation of capillary-like structures by human endothelial cells as well as suppression of microvessel outgrowth in rat aortic rings and rat cornea angiogenesis.
  • Furthermore, GFA-116 is also effective at inhibiting tumor growth and metastasis to the lung of B16-F10 melanoma cells injected into immunocompetent mice.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Benzoates / pharmacology. Neovascularization, Pathologic / drug therapy. Peptides, Cyclic / pharmacology. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Animals. Brain / blood supply. Cell Line, Tumor. Cornea / blood supply. Endothelium, Vascular / drug effects. Endothelium, Vascular / growth & development. Endothelium, Vascular / metabolism. Humans. Lung Neoplasms / blood supply. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Melanoma, Experimental / blood supply. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Mice. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3. Mitogen-Activated Protein Kinases / metabolism. NIH 3T3 Cells. Neovascularization, Physiologic / drug effects. Phosphorylation. Prostatic Neoplasms / blood supply. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism. Rats. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15150116.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA78038; United States / NIGMS NIH HHS / GM / GM35208
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Benzoates; 0 / GFA 116; 0 / Peptides, Cyclic; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


6. Bouïs D, Hospers GA, Meijer C, Dam W, Mulder NH: CDT6-expression can alter tumor sensitivity to chemotherapy. Anticancer Res; 2003 Jan-Feb;23(1A):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDT6-expression can alter tumor sensitivity to chemotherapy.
  • BACKGROUND: Cornea-derived transcript 6 (CDT6 = AngX) has been shown to have an anti-tumor effect.
  • MATERIALS AND METHODS: We transfected the murine melanoma cell line B16-F10 with the CDT6 gene and compared the sensitivity to cytostatic drugs of the resulting cell line, B16-CDT6, to that of the empty vector-transfected control cell line B16-CMV.
  • However no difference in sensitivity for these drugs was found between the B16-CDT6 and the control cell line.
  • Altered gene expression induced by gene therapy might influence tumor sensitivity to chemotherapy.
  • [MeSH-major] Angiogenesis Inducing Agents / genetics. Antineoplastic Agents / pharmacology. Genetic Therapy / methods. Melanoma, Experimental / therapy
  • [MeSH-minor] Animals. Cisplatin / pharmacology. Cloning, Molecular. Combined Modality Therapy. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Etoposide / pharmacology. Mice. Paclitaxel / pharmacology. Transfection. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12680246.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Bouïs D, Hospers GA, Meijer C, Dam W, Peek R, Mulder NH: Effects of the CDT6/ANGX gene on tumour growth in immune competent mice. In Vivo; 2003 Mar-Apr;17(2):157-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cornea-derived transcript 6 (CDT6, also known as AngX) has been described to inhibit tumour growth in a human melanoma growing in nude mice.
  • MATERIALS AND METHODS: In this report we describe the generation of a stably CDT6-expressing clone of the murine melanoma cell line B16-F10.
  • RESULTS: We found no significant inhibition or stimulation of either lag-time or doubling-time of the tumours.
  • [MeSH-major] Angiogenesis Inducing Agents / therapeutic use. Angiogenic Proteins / genetics. Genetic Therapy / methods. Immunocompetence. Melanoma, Experimental / therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Division / drug effects. Cell Line, Tumor. Endothelium, Vascular / drug effects. Endothelium, Vascular / pathology. Female. Humans. Mice. Mice, Inbred C57BL. Mice, Nude. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792978.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Angiogenic Proteins; 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


8. Shields JA, Shields CL, Mashayekhi A, Marr BP, Benavides R, Thangappan A, Phan L, Eagle RC Jr: Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture. Ophthalmology; 2008 Mar;115(3):511-519.e2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture.
  • PURPOSE: To evaluate the clinical features and risks for transformation of conjunctival primary acquired melanosis (PAM) into melanoma.
  • PARTICIPANTS: Three hundred eleven eyes with conjunctival PAM without melanoma at initial examination from a single-center tertiary referral center.
  • Times to PAM enlargement, recurrence, and transformation into melanoma were assessed using Kaplan-Meier estimates.
  • MAIN OUTCOME MEASURES: Primary acquired melanosis enlargement, recurrence, and transformation into melanoma.
  • The anatomic location(s) of PAM included bulbar conjunctiva (91%), limbal conjunctiva (55%), cornea (23%), forniceal conjunctiva (13%), palpebral conjunctiva (12%), and caruncle (11%).
  • Initial management included observation (n = 194 eyes [62%]), biopsy combined with cryotherapy (n = 107 eyes [34%]), and topical chemotherapy and/or cryotherapy without biopsy (n = 10 [4%]).
  • Of PAM that was observed, Kaplan-Meier estimates at 10 years revealed PAM enlargement in 35% and transformation into melanoma in 12%.
  • Of those that underwent incisional or excisional biopsy, 10-year estimates of PAM recurrence and transformation into melanoma were 58% and 11%, respectively.
  • Progression to melanoma occurred in 0% of cases of PAM without atypia, 0% of cases of PAM with mild atypia, and 13% of cases of PAM with severe atypia.
  • Of the 9 patients with PAM who developed melanoma, none have developed systemic metastasis.
  • Multivariable analysis revealed that the most significant factor for both PAM recurrence and progression to melanoma was extent of PAM in clock hours.
  • CONCLUSION: Primary acquired melanosis without atypia or with mild atypia shows 0% progression to melanoma, whereas PAM with severe atypia shows progression to melanoma in 13%.
  • The greater the extent of PAM in clock hours, the greater the risk for transformation to melanoma.
  • [MeSH-major] Conjunctival Diseases / pathology. Conjunctival Neoplasms / pathology. Melanoma / pathology. Melanosis / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884168.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Jain V, Dabir S, Shome D, Dadu T, Natarajan S: Aspergillus iris granuloma: a case report with review of literature. Surv Ophthalmol; 2009 Mar-Apr;54(2):286-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential diagnoses of a fungal granuloma, a medulloepithelioma, and an amelanotic melanoma were considered.
  • An excisional biopsy of the mass was performed through a superior clear corneal incision.
  • Definitive differentiation of this rare entity from a foreign body, amelanotic melanoma, and other inflammatory conditions such as sarcoidosis and tuberculosis, may be possible only on microbiological and histo-pathological evaluation.
  • [MeSH-minor] Adult. Antifungal Agents / therapeutic use. Aqueous Humor / microbiology. Atropine / therapeutic use. Aza Compounds / therapeutic use. DNA, Fungal / analysis. Drug Therapy, Combination. Fluoroquinolones. Genome, Fungal / genetics. Humans. Male. Natamycin / therapeutic use. Polymerase Chain Reaction. Quinolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. ATROPINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298905.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Aza Compounds; 0 / DNA, Fungal; 0 / Fluoroquinolones; 0 / Quinolines; 7C0697DR9I / Atropine; 8O0C852CPO / Natamycin; U188XYD42P / moxifloxacin
  • [Number-of-references] 18
  •  go-up   go-down


10. Kabasawa S, Murayama K, Tsuchida T, Tanaka K, Arai E, Yoneya S: [Case of corneally displaced malignant conjunctival melanoma]. Nippon Ganka Gakkai Zasshi; 2007 Feb;111(2):102-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of corneally displaced malignant conjunctival melanoma].
  • BACKGROUND: We studied the clinicopathologic characteristics in a patient with malignant conjunctival melanoma associated with corneal invasion.
  • He developed recurrence and was referred to us.
  • Biomicroscopic examination revealed that there was a granular pigment lesion in the cornea.
  • The patient was diagnosed as having conjunctival melanoma with corneal invasion and treated with orbital exenteration and chemotherapy in our hospital.
  • Clinicopathologic tests revealed malignant melanoma cells invading through the bulbar conjunctiva and into the cornea.
  • Ultrastructural study by electron microscopy of the pigmented tumor cells in the cornea showed several lobations of the nuclei, a large active-appearing nucleolus, and an aberrant granular melanosomal morphology.
  • CONCLUSIONS: The infiltration of palpebral malignant conjunctival melanoma was limited to the epidermis of the cornea.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Corneal Diseases / pathology. Eye Neoplasms / pathology. Melanoma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Male. Microscopy, Electron. Middle Aged. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures. Prognosis

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338327.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Ley RD, Reeve VE, Kusewitt DF: Photobiology of Monodelphis domestica. Dev Comp Immunol; 2000 Jul;24(5):503-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of a light-activated DNA repair pathway in the tissues of Monodelphis has been used to identify pyrimidine dimers in DNA as initiating events for a number of ultraviolet radiation (UVR)-induced pathologies of the skin and cornea.
  • Furthermore, Monodelphis, unlike common laboratory rodents, is susceptible to the induction of melanoma by UVR alone.
  • [MeSH-major] Cornea / radiation effects. DNA Repair. Opossums. Skin / radiation effects. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Animals. Dermatitis, Contact / drug therapy. Dinitrofluorobenzene / pharmacology. Disease Models, Animal. Eye Neoplasms / etiology. Melanoma / etiology. Mice. Mice, Nude. Oxazolone / pharmacology. Photobiology. Pyrimidine Dimers / radiation effects. Skin Neoplasms / etiology. Urocanic Acid / analysis

  • Hazardous Substances Data Bank. 1-FLUORO-2,4-DINITROBENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10785275.001).
  • [ISSN] 0145-305X
  • [Journal-full-title] Developmental and comparative immunology
  • [ISO-abbreviation] Dev. Comp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Pyrimidine Dimers; 15646-46-5 / Oxazolone; D241E059U6 / Dinitrofluorobenzene; G8D26XJJ3B / Urocanic Acid
  • [Number-of-references] 52
  •  go-up   go-down


12. Ambrus JL, Toumbis CA, Karakousis CP, Kulaylat M, Akhter S, Plavsic L: Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration. J Med; 2000;31(5-6):278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration.
  • Using a previously developed method (Ambrus, et al., 1991), we found that pentoxifylline and thalidomide potentiate each others antiangiogenic effect induced by human malignant melanoma cells in the cornea of Macaca arctoides monkeys.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Cornea / drug effects. Corneal Neovascularization / drug therapy. Melanoma / pathology. Pentoxifylline / pharmacology. Thalidomide / pharmacology
  • [MeSH-minor] Animals. Cells, Cultured. Drug Combinations. Enzyme Inhibitors / pharmacology. Humans. Keratinocytes. Macaca. Macular Degeneration / drug therapy

  • Genetic Alliance. consumer health - Macular Degeneration.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11508321.001).
  • [ISSN] 0025-7850
  • [Journal-full-title] Journal of medicine
  • [ISO-abbreviation] J Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 4Z8R6ORS6L / Thalidomide; SD6QCT3TSU / Pentoxifylline
  •  go-up   go-down


13. Khong JJ, Muecke J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol; 2006 Jul;90(7):819-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
  • AIM: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.
  • Outcome measures included complications of MMC and the treatment required for these complications.
  • RESULTS: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma.
  • 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.
  • CONCLUSION: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Drug Hypersensitivity / etiology. Eye Neoplasms / drug therapy. Mitomycin / adverse effects
  • [MeSH-minor] Adenocarcinoma, Sebaceous / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / drug therapy. Humans. Lacrimal Apparatus Diseases / chemically induced. Lacrimal Duct Obstruction / chemically induced. Male. Melanoma / drug therapy. Melanosis / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Allergy. 1997 Jun;52(6):687 [9226075.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Ophthalmology. 2001 May;108(5):994-5 [11320034.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):216-24 [12918558.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1422-4 [15489486.001]
  • [Cites] Br J Dermatol. 1990 Feb;122(2):217-24 [2138492.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):807-9 [16782942.001]
  • (PMID = 16672325.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1857172
  •  go-up   go-down


14. Ciralsky J, Colby K: Conjunctival melanomas: can the cancer stem cell hypothesis be applied? Semin Ophthalmol; 2009 May-Jun;24(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conjunctival melanoma patients often follow an unpredictable course with significant rates of recurrence and metastases despite optimal treatment.
  • Targeting cancer stem cells may be the key to future treatments.
  • Directed treatments need to focus on key differences between cancer stem cells and normal tissue stem cells.
  • These directed treatments may lead to curative therapies and decrease the number of recurrences and metastases.
  • [MeSH-major] Conjunctival Neoplasms / etiology. Melanoma / etiology. Neoplastic Stem Cells / physiology
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Animals. Antineoplastic Agents / therapeutic use. Humans. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437352.001).
  • [ISSN] 1744-5205
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


15. Schallenberg M, Niederdräing N, Steuhl KP, Meller D: [Topical Mitomycin C as a therapy of conjunctival tumours]. Ophthalmologe; 2008 Aug;105(8):777-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical Mitomycin C as a therapy of conjunctival tumours].
  • [Transliterated title] Topisches Mitomycin C als Therapie konjunktivaler Tumore.
  • Therefore, alternative or adjuvant therapies are required.
  • Topical chemotherapy with mitomycin C (MMC) is increasingly finding use in clinical practice.
  • MMC seems to be an option for the treatment of primary acquired melanosis (PAM); but, if the tumour is suspicious for melanoma primary chemotherapy with MMC is obsolete.
  • In these cases MMC can only be used as an adjuvant therapy, otherwise tumour control is not assured.
  • However, prospective randomized controlled trials are necessary for a final evaluation of MMC therapy in melanocytic tumours of the conjunctiva.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Melanoma / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Drug Hypersensitivity / etiology. Humans. Melanosis / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Biochem. 1978 Nov;56(11):1042-7 [216472.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3164-71 [16809739.001]
  • [Cites] Hum Pathol. 1985 Feb;16(2):136-43 [3972396.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Ophthalmology. 2000 May;107(5):951-8 [10811089.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1990 Oct 15;110(4):412-5 [2220977.001]
  • [Cites] Hum Pathol. 1985 Feb;16(2):129-35 [3972395.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] Arch Ophthalmol. 1975 Feb;93(2):119-22 [1115670.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1108-14 [15940485.001]
  • [Cites] Mutat Res. 1987 Jul;179(1):75-88 [3110608.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):317-21 [2023752.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Am J Ophthalmol. 1988 Dec 15;106(6):715-8 [3143266.001]
  • [Cites] Cornea. 2003 Mar;22(2):114-7 [12605043.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1511-3 [8932327.001]
  • [Cites] Br J Ophthalmol. 2002 Jan;86(1):31-4 [11801499.001]
  • [Cites] Science. 1987 Mar 6;235(4793):1204-8 [3103215.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 Mar;19(2):149-51 [12644763.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):310-6 [15377990.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Int Ophthalmol Clin. 1982 Fall;22(3):1-33 [7107129.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812-5 [6304740.001]
  • [Cites] Ophthalmology. 1992 Feb;99(2):203-7 [1553208.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthalmology. 2007 May;114(5):976-82 [17241666.001]
  • [Cites] Anticancer Drugs. 1990 Oct;1(1):5-13 [2131038.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Cornea. 2003 Oct;22(7):687-704 [14508267.001]
  • [Cites] Arch Ophthalmol. 2000 Nov;118(11):1497-507 [11074806.001]
  • [Cites] Am J Ophthalmol. 2005 Feb;139(2):229-34 [15733981.001]
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • [Cites] Cancer Treat Rev. 1976 Sep;3(3):121-39 [786455.001]
  • [Cites] Am J Ophthalmol. 2001 Oct;132(4):576-8 [11589886.001]
  • [Cites] Ophthalmologe. 2003 Sep;100(9):708-12 [14504895.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Am J Ophthalmol. 2008 Jan;145(1):124-129 [17981257.001]
  • [Cites] Cornea. 2006 Dec;25(10 ):1220-3 [17172902.001]
  • [Cites] Br J Ophthalmol. 2006 Jul;90(7):819-22 [16672325.001]
  • [Cites] Cornea. 2005 May;24(4):443-8 [15829803.001]
  • [Cites] Ophthalmologica. 2007;221(1):14-7 [17183195.001]
  • [Cites] Chem Biol Interact. 1976 Apr;13(1):89-97 [770011.001]
  • [Cites] Ophthalmologe. 2006 Feb;103(2):124-8 [16047150.001]
  • [Cites] Arch Ophthalmol. 1999 Apr;117(4):544-5 [10206591.001]
  • [Cites] Eye (Lond). 2003 Mar;17(2):228-32 [12640411.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 Apr;244(4):438-46 [16133022.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • (PMID = 18618124.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Number-of-references] 62
  •  go-up   go-down


16. Chalasani R, Giblin M, Conway RM: Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment. Clin Exp Ophthalmol; 2006 Sep-Oct;34(7):708-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment.
  • Surgical excision with cryotherapy is a well-established treatment option for malignant melanoma or primary acquired melanosis (PAM) with atypia of the conjunctiva and cornea.
  • Relevant studies were reviewed with regards to treatment regimen, rates of recurrence and metastasis, side effect profile and length of follow up.
  • A total of 22 and 16 unique cases of biopsy proven PAM with atypia and malignant melanoma, respectively, treated with topical MMC were identified.
  • Topical MMC was well tolerated and shows considerable promise, particularly in the treatment of diffuse PAM with atypia.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Melanoma / drug therapy. Melanosis / drug therapy. Mitomycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16970772.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Number-of-references] 31
  •  go-up   go-down


17. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res; 2006 Jan 1;66(1):221-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show here that FTY720 has antiangiogenic activity, potently abrogating VEGF- and S1P-induced angiogenesis in vivo in growth factor implant and corneal models.
  • FTY720 administration tended to inhibit primary and significantly inhibited metastatic tumor growth in a mouse model of melanoma growth.
  • These data show that functional antagonism of vascular S1P receptors by FTY720 potently inhibits angiogenesis; therefore, this may provide a novel therapeutic approach for pathologic conditions with dysregulated angiogenesis.
  • [MeSH-major] Melanoma, Experimental / blood supply. Melanoma, Experimental / drug therapy. Propylene Glycols / pharmacology. Receptors, Lysosphingolipid / antagonists & inhibitors
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Growth Processes / drug effects. Cell Movement / drug effects. Cornea / blood supply. Endothelial Cells / drug effects. Endothelial Cells / enzymology. Female. Fingolimod Hydrochloride. Humans. Mice. Mitogen-Activated Protein Kinases / metabolism. Neovascularization, Pathologic / drug therapy. Neovascularization, Physiologic / drug effects. Phosphorylation. Phthalazines / pharmacology. Pyridines / pharmacology. Sphingosine / analogs & derivatives. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397235.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phthalazines; 0 / Propylene Glycols; 0 / Pyridines; 0 / Receptors, Lysosphingolipid; 0 / Vascular Endothelial Growth Factor A; 5DX9U76296 / vatalanib; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; G926EC510T / Fingolimod Hydrochloride; NGZ37HRE42 / Sphingosine; SY7Q814VUP / Calcium
  •  go-up   go-down


18. Herold TR, Hintschich C: Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol; 2010 Jan;248(1):111-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha for the treatment of melanocytic conjunctival lesions.
  • BACKGROUND: To evaluate the effect of topical interferon alpha-2b therapy in the treatment of melanocytic conjunctival lesions.
  • METHODS: Nine patients with histologically proven acquired melanosis with atypia and/or conjunctival melanoma were treated with recombinant IFN alpha-2b (Intron A, Essex Pharma, Luzern, Switzerland).
  • The patients were seen after 2 weeks and after the end of the treatment.
  • Endpoint of the treatment was the complete regression of pigmentation or absence of cytological atypia in a re-biopsy.
  • Three patients required a second cycle after the first therapy because of incomplete regression and one patient needed a third cycle of interferon.
  • Only one of the patients needed a fourth cycle of therapy and additional surgery to show stable regression.
  • The pre- and post-treatment photos of two cases will be presented.
  • CONCLUSIONS: Our observations suggest that topical interferon alpha-2b might be an effective agent for the adjuvant treatment of melanocytic conjunctival tumors without side-effects.
  • A prospective multicenter study will help to finally evaluate the potential of topical interferon therapy for melanocytic conjunctival tumors, in particular PAM with atypia and minimal invasive conjunctival melanoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Interferon-alpha / administration & dosage. Melanoma / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Conjunctival Diseases / drug therapy. Female. Humans. Male. Melanosis / drug therapy. Middle Aged. Prospective Studies. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cornea. 2004 Jan;23 (1):89-92 [14701965.001]
  • [Cites] Arch Dermatol. 2000 Nov;136(11):1415-6 [11074712.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67 [13465720.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1755-61 [15350333.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] J Ocul Pharmacol Ther. 2007 Apr;23 (2):143-5 [17444802.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Am J Ophthalmol. 2008 Jan;145(1):124-129 [17981257.001]
  • [Cites] Ophthalmologe. 2006 Feb;103(2):124-8 [16047150.001]
  • [Cites] Orbit. 2002 Sep;21(3):231-8 [12187419.001]
  • [Cites] Semin Ophthalmol. 2006 Jul-Sep;21(3):161-9 [16912014.001]
  • [Cites] Optometry. 2007 Apr;78(4):162-6 [17400137.001]
  • (PMID = 19756691.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b
  •  go-up   go-down






Advertisement